CXCR1 and neoplasm: We then demonstrate the plasticity of this phenotype in vivo and ex vivo by re-sensitizing the tumor cells to chemotherapy using CXCR1/2 receptor inhibitors, which may be a promising therapeutic strategy to circumvent resistances in patients.